NO20060716L - Krystallinske former av `R-(Rx,)-2(4-fluorfenyl)-beta, delta-dihydroksy-5-(1metyletyl)-3-fenyl-4-`(fenylamino) karbonyl-1H-pyrrol-1-hetpansyre - Google Patents
Krystallinske former av `R-(Rx,)-2(4-fluorfenyl)-beta, delta-dihydroksy-5-(1metyletyl)-3-fenyl-4-`(fenylamino) karbonyl-1H-pyrrol-1-hetpansyreInfo
- Publication number
- NO20060716L NO20060716L NO20060716A NO20060716A NO20060716L NO 20060716 L NO20060716 L NO 20060716L NO 20060716 A NO20060716 A NO 20060716A NO 20060716 A NO20060716 A NO 20060716A NO 20060716 L NO20060716 L NO 20060716L
- Authority
- NO
- Norway
- Prior art keywords
- phenylamino
- methylethyl
- fluorophenyl
- pyrrole
- dihydroxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Abstract
Nye krystallinske former av [R-(R*,R*)]-2-(4-fluorfenyl)-p,8-dihydroksy-5-(1 -metyletyl)-3-fenyl-4-[(fenylamino)karbonyl]-1 H-pyrrol-1 -heptansyre (atorvastatin fri syre) betegnet form A og form B, karakterisert ved deres røntgen-pulverdiffraksjonsmønster og faststoff NMR-spektra er beskrevet, så vel som metoder for fremstilling og farmasøytisk preparat av samme, som er anvendelige som midler for behandling av hyperlipidemi, hyperkolesterolemi, osteoporose, godartet prostatisk hyperplasi og Alzheimers sykdom og for fremstilling av salter av atorvastatin.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50359203P | 2003-09-17 | 2003-09-17 | |
PCT/IB2004/002919 WO2005026116A1 (en) | 2003-09-17 | 2004-09-06 | Crystalline forms of `r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-`(phenylamino)carbonyl!-1h-pyrrole-1-heptanoic acid |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20060716L true NO20060716L (no) | 2006-06-16 |
Family
ID=34312443
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20060716A NO20060716L (no) | 2003-09-17 | 2006-02-14 | Krystallinske former av `R-(Rx,)-2(4-fluorfenyl)-beta, delta-dihydroksy-5-(1metyletyl)-3-fenyl-4-`(fenylamino) karbonyl-1H-pyrrol-1-hetpansyre |
Country Status (16)
Country | Link |
---|---|
US (1) | US20070276027A1 (no) |
EP (1) | EP1663969A1 (no) |
JP (1) | JP2007505885A (no) |
KR (1) | KR100781420B1 (no) |
CN (2) | CN101318923A (no) |
AR (1) | AR045654A1 (no) |
AU (1) | AU2004272365A1 (no) |
BR (1) | BRPI0414457A (no) |
CA (1) | CA2539158A1 (no) |
IL (1) | IL173651A0 (no) |
MX (1) | MXPA06003003A (no) |
NO (1) | NO20060716L (no) |
RU (1) | RU2315755C2 (no) |
TW (1) | TW200524862A (no) |
WO (1) | WO2005026116A1 (no) |
ZA (1) | ZA200602222B (no) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200745026A (en) | 2005-12-13 | 2007-12-16 | Teva Pharma | Crystal form of atorvastatin hemi-calcium and processes for preparation thereof |
NZ579736A (en) * | 2007-04-13 | 2012-02-24 | Nicox Sa | Crystalline forms of atorvastatin 4-(nitrooxy) butyl ester |
US8697740B2 (en) | 2009-01-12 | 2014-04-15 | Merck Sharp & Dohme Corp. | Crystalline polymorphic forms of an antidiabetic compound |
CA2706270C (en) * | 2010-06-03 | 2020-01-07 | Accucaps Industries Limited | Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation |
CA3065589C (en) | 2010-06-03 | 2022-04-26 | Catalent Ontario Limited | Multi phase soft gel capsules, apparatus and method thereof |
KR20120011249A (ko) | 2010-07-28 | 2012-02-07 | 주식회사 경보제약 | 아토바스타틴 헤미칼슘염의 신규한 결정형, 이의 수화물, 및 그의 제조방법 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US5149837A (en) * | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5003080A (en) * | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
US5216174A (en) * | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5097045A (en) * | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
US5124482A (en) * | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
US5245047A (en) * | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5103024A (en) * | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5248793A (en) * | 1990-10-17 | 1993-09-28 | Warner-Lambert Company | Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
US5155251A (en) * | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
US5213995A (en) * | 1992-04-16 | 1993-05-25 | At&T Bell Laboratories | Method of making an article comprising a periodic heteroepitaxial semiconductor structure |
CA2150372C (en) * | 1993-01-19 | 2002-08-20 | Nancy L. Mills | Stable oral ci-981 formulation and process of preparing same |
US5298627A (en) * | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
SI0848705T1 (en) * | 1995-07-17 | 2002-04-30 | Warner-Lambert Company | Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin) |
HRP960313B1 (en) * | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
US5998633A (en) * | 1996-07-29 | 1999-12-07 | Warner-Lambert Company | Process for the synthesis of protected esters of (S)-3,4-dihydroxybutyric acid |
WO1999032434A1 (en) * | 1997-12-19 | 1999-07-01 | Warner-Lambert Export Limited | Process for the synthesis of 1,3-diols |
SI20070A (sl) | 1998-09-18 | 2000-04-30 | LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. | Nove soli inhibitorjev HMG-CoA reduktaze |
PL362981A1 (en) * | 2000-11-16 | 2004-11-02 | Teva Pharmaceutical Industries Ltd. | Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-beta,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide |
US6476235B2 (en) * | 2001-01-09 | 2002-11-05 | Warner-Lambert Company | Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide |
-
2004
- 2004-09-06 CN CNA2008101341489A patent/CN101318923A/zh active Pending
- 2004-09-06 AU AU2004272365A patent/AU2004272365A1/en not_active Abandoned
- 2004-09-06 CN CNA2004800269756A patent/CN1852894A/zh active Pending
- 2004-09-06 WO PCT/IB2004/002919 patent/WO2005026116A1/en active Application Filing
- 2004-09-06 CA CA002539158A patent/CA2539158A1/en not_active Abandoned
- 2004-09-06 MX MXPA06003003A patent/MXPA06003003A/es unknown
- 2004-09-06 BR BRPI0414457-0A patent/BRPI0414457A/pt not_active IP Right Cessation
- 2004-09-06 US US10/572,324 patent/US20070276027A1/en not_active Abandoned
- 2004-09-06 JP JP2006526717A patent/JP2007505885A/ja active Pending
- 2004-09-06 RU RU2006108385/04A patent/RU2315755C2/ru not_active IP Right Cessation
- 2004-09-06 EP EP04769318A patent/EP1663969A1/en not_active Withdrawn
- 2004-09-06 KR KR1020067005316A patent/KR100781420B1/ko not_active IP Right Cessation
- 2004-09-15 TW TW093127885A patent/TW200524862A/zh unknown
- 2004-09-15 AR ARP040103296A patent/AR045654A1/es unknown
-
2006
- 2006-02-09 IL IL173651A patent/IL173651A0/en unknown
- 2006-02-14 NO NO20060716A patent/NO20060716L/no not_active Application Discontinuation
- 2006-03-16 ZA ZA200602222A patent/ZA200602222B/en unknown
Also Published As
Publication number | Publication date |
---|---|
RU2315755C2 (ru) | 2008-01-27 |
AU2004272365A1 (en) | 2005-03-24 |
CA2539158A1 (en) | 2005-03-24 |
CN101318923A (zh) | 2008-12-10 |
KR20060037467A (ko) | 2006-05-03 |
KR100781420B1 (ko) | 2007-12-03 |
JP2007505885A (ja) | 2007-03-15 |
IL173651A0 (en) | 2006-07-05 |
BRPI0414457A (pt) | 2006-11-14 |
RU2006108385A (ru) | 2006-08-10 |
AR045654A1 (es) | 2005-11-02 |
MXPA06003003A (es) | 2006-06-23 |
WO2005026116A1 (en) | 2005-03-24 |
EP1663969A1 (en) | 2006-06-07 |
CN1852894A (zh) | 2006-10-25 |
US20070276027A1 (en) | 2007-11-29 |
ZA200602222B (en) | 2007-07-25 |
TW200524862A (en) | 2005-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005105738A3 (en) | Salt forms of atorvastatin | |
AP1571A (en) | Crystalline forms of 'R-(R* ,R*)!-2-(4- fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-'phenylamino)carbonyl!-1H-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin) | |
EE9800016A (et) | Vorm III kristalliline [R-(R*,R*)]-2-(4-fluorofenüül)-beeta, delta-dihüdroksü-5-(1-metüületüül)-3-fenüül-4-[(fenüülamino)karbonüül]-1H-pürrool-1-hepta anhappe hemikaltsiumsool (atorvastatiin) | |
DK0839132T5 (da) | Fremgangsmåde til fremstilling af amorft [R-(R*,R*)]-2-(4-fluorphenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrol-1-heptansyrecalciumsalt (2:1) | |
NZ312907A (en) | Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl | |
CA2435954A1 (en) | Preparation of non-crystalline atorvastatin calcium | |
NO20060716L (no) | Krystallinske former av `R-(Rx,)-2(4-fluorfenyl)-beta, delta-dihydroksy-5-(1metyletyl)-3-fenyl-4-`(fenylamino) karbonyl-1H-pyrrol-1-hetpansyre | |
NZ533935A (en) | Crystalline [R-(R*,R*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-heptanoic acid calcium salt (2:1) | |
TW200738624A (en) | Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium | |
WO2006011041A3 (en) | Crystalline forms of (r-(r*))-2-(4-fluorophenyl)-beta, gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1h-pyrrole-1-hept anoic acid calcium salt (2:1) | |
CA2522899A1 (en) | Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin) | |
HUP0600120A2 (en) | New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it | |
TH61086A (th) | รูปแบบผลึกของเกลือแคลเซียม (2 | |
CY1110165T1 (el) | Νεες μορφες αλατος μαγνησιου του [r-(r*,r*)]-2-(4-φθοροφαινυλ)-β,β-διυδροξυ-5-(1-μεθυλαιθυλ)-3-5 φαινυλ-4-[(φαινυλαμινο)καρβονυλ]-1η-πυρρολο-1-επτανοϊκου οξεος |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |